Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

MDLinx announces new Omnibus offering for international pharmaceutical market research

MDLinx, a division of M3 USA, announced today a new Omnibus offering for international pharmaceutical market research. The new offering, launched at the Pharmaceutical Market Research Conference, enables market researchers a new, simplified, reduced-cost means of accessing specialty physicians around the world.

2 Feb 2010

ADT can worsen heart risk factors and may increase the risk of heart attack

Androgen-deprivation therapy (ADT), commonly used to treat prostate cancer, can worsen heart risk factors and may increase the risk of heart attack and/or cardiac death, although the relationship between ADT and heart attack or cardiac death has not been definitively established, according to a science advisory published in Circulation: Journal of the American Heart Association and CA: A Cancer Journal for Clinicians.

2 Feb 2010

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."

2 Feb 2010

IMRT and extensive safety measures can prevent radiation injuries in cancer patients, says oncology expert

Recent media stories have reported isolated cases of cancer patients who were injured by incorrect doses from intensity-modulated radiation therapy (IMRT).

2 Feb 2010

Cephalon to acquire Swiss-based pharmaceutical company

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Managing Myeloma (www.ManagingMyeloma.com) convened the 2010 Multidisciplinary Advisory Board on January 16, 2010 to review the past 18 months and discuss the educational and practical needs of myeloma practitioners in an evolving therapeutic landscape.

1 Feb 2010

Asuragen enters into research agreements to develop microRNA-based diagnostic test

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has entered into research agreements with The University of Pittsburgh Medical Center, Brigham and Women’s Hospital, the H. Lee Moffitt Cancer Center, Dartmouth’s Hitchcock Medical Center and the University of Sherbrooke to develop a microRNA-based diagnostic test to aid the detection of pancreatic cancer from fine-needle aspirate (FNA) biopsies.

1 Feb 2010

Ipsen reports consolidated group sales of €1,032.8M for 2009

Ipsen reported today its sales for the fourth quarter and full year 2009.

1 Feb 2010

Enzo Biochem generating more than $100M in revenues annually

Enzo Biochem, Inc. is well positioned to benefit from the results of its transformation involving acquisitions, new managements at each of its major subsidiaries and a heightened focus on new life science, diagnostic and therapeutic products, Barry Weiner, President, told the annual meeting of shareholders today.

30 Jan 2010

Society publication strengthens oncology journals program

Beginning this year, Springer will add the Journal of Cancer Education (JCE) to its journals publishing program. Published on behalf of the American Association for Cancer Education and the European Association for Cancer Education, the quarterly journal features a varied editorial board made up of MDs and PhDs who support the dissemination of information on improving cancer education worldwide.

30 Jan 2010

Spectrum Pharmaceuticals receives $16M over apaziquone collaboration agreement

Spectrum Pharmaceuticals, Inc., announced today that it has received $15 million from Nippon Kayaku in connection with the collaboration agreement for apaziquone (EOquin®) announced on November 10, 2009, and $1 million from Handok Pharmaceuticals announced on November 23, 2009.

30 Jan 2010

FDA approved 53 new oncology and hematology drugs between 2005 and 2007

Over a two and half year period, beginning in 2005 when the U.S. Food and Drug Administration's oncology drug product's office began reviewing marketing applications, a total of 60 new oncology and hematology drugs were reviewed, of which 53 were approved, according to a new article published online January 29 in the Journal of the National Cancer Institute.

30 Jan 2010

Congressman Rothman secures 1.49M in federal dollars for EHMC's bloodless medicine program

Congressman Steve Rothman (D-NJ) will be the featured speaker at Englewood Hospital and Medical Center today, 1:00-2:00 pm. Congressman Rothman will announce the latest batch of federal funds, $1.49 million, for the Institute for Patient Blood Management and Bloodless Medicine and Surgery. This brings the total amount of federal funding secured by Congressman Rothman for this institute to $4.69 million in federal resources and to over six million dollars to Hospital programs since 2002.

30 Jan 2010

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

Salient Surgical Technologies of Portsmouth, New Hampshire, has partnered with Exeter Hospital in Exeter, New Hampshire and Moffitt Cancer Center in Tampa, Florida, to donate equipment and supplies for a mission to aid victims of the January 12 earthquake in Haiti.

30 Jan 2010

AAPM reassures safety of radiation therapy

The American Association of Physicists in Medicine (AAPM) has issued a statement today in the wake of several recent articles in the New York Times yesterday and earlier in the week that discuss a number of rare but tragic events in the last decade involving people undergoing radiation therapy.

30 Jan 2010

Redwood Consultants to assist DMI Life Sciences in shareholder relations and investor communications

DMI Life Sciences, Inc., which recently announced that it has entered into a non-binding letter of intent with Imagine Media, Ltd. is pleased to announce today that the Company has retained California-based Redwood Consultants, LLC to assist in shareholder relations and investor communications.

30 Jan 2010

Northwestern Memorial HealthCare completes its formal plans to affiliate with Lake Forest Hospital

Northwestern Memorial HealthCare has completed its formal plans to affiliate with Lake County's Lake Forest Hospital. Northwestern's health system has obtained both federal and state approvals to proceed with an affiliation agreement that will make Lake Forest Hospital a wholly owned entity of Northwestern Memorial HealthCare along with Northwestern Memorial Hospital on February 1, 2010.

30 Jan 2010

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

30 Jan 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Oncology News and Research

Further Reading

MDLinx announces new Omnibus offering for international pharmaceutical market research

ADT can worsen heart risk factors and may increase the risk of heart attack

BRI partners with French Government to create therapeutic antibodies for treatment of major diseases

IMRT and extensive safety measures can prevent radiation injuries in cancer patients, says oncology expert

Cephalon to acquire Swiss-based pharmaceutical company

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Managing Myeloma reviews past accomplishments; discusses future goals in evolving therapeutic landscape

Asuragen enters into research agreements to develop microRNA-based diagnostic test

Ipsen reports consolidated group sales of €1,032.8M for 2009

Enzo Biochem generating more than $100M in revenues annually

Society publication strengthens oncology journals program

Spectrum Pharmaceuticals receives $16M over apaziquone collaboration agreement

FDA approved 53 new oncology and hematology drugs between 2005 and 2007

Congressman Rothman secures 1.49M in federal dollars for EHMC's bloodless medicine program

Salient Surgical Technologies, Exeter Hospital and Moffitt Cancer Center donate medical supplies to Haiti

AAPM reassures safety of radiation therapy

Redwood Consultants to assist DMI Life Sciences in shareholder relations and investor communications

Northwestern Memorial HealthCare completes its formal plans to affiliate with Lake Forest Hospital

FDA approves new drug combination for hormone positive and HER2-positive advanced breast cancer

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Cancer Research eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News